Welcome to our dedicated page for Adial Pharmaceuticals news (Ticker: ADIL), a resource for investors and traders seeking the latest updates and insights on Adial Pharmaceuticals stock.
Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) is a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addictions and related disorders. News about Adial often centers on the progress of its lead investigational drug, AD04, a genetically targeted serotonin-3 receptor antagonist being developed for Alcohol Use Disorder (AUD) in heavy drinking patients with specific genotypes.
On this page, readers can find coverage of Adial’s clinical development milestones, including updates on the ONWARD™ pivotal Phase 3 trial and preparations for a new Phase 3 adaptive program informed by End of Phase 2 (EOP2) feedback from the U.S. Food and Drug Administration (FDA). Company announcements describe FDA recognition of AUD as an unmet need, support for Adial’s adaptive trial design, and confirmation of primary efficacy endpoints based on heavy drinking days.
Adial’s news flow also highlights its precision medicine strategy. Releases describe a partnership with Genomind to validate a cheek swab genetic test that identifies SNPs in serotonergic system genes such as HTR3A, HTR3B, and SLC6A4, enabling selection of biomarker-positive patients, including those with the AG+ genotype. Additional stories cover intellectual property developments, such as provisional and international patent applications for AD04 that the company expects, once granted, to protect core assets to at least 2045.
Investors and observers can also follow capital markets and listing-related updates, including public offerings of stock and warrants, at-the-market sales agreements, Nasdaq compliance notices, and extensions related to minimum bid price requirements. Together, these items provide context on how Adial is financing and structuring its efforts to advance AD04 and its broader addiction treatment pipeline. Bookmark this page to review new regulatory, clinical, financing, and intellectual property announcements as they are reported.
Adial Pharmaceuticals (NASDAQ: ADIL; ADILW) announced the completion of a $5,000,002 private placement of 1,666,668 shares at $3.00 each, funding its ONWARD™ Phase 3 trial for AD04, a treatment for Alcohol Use Disorder (AUD). The financing, totaling $7.1 million when combined with a previous round, supports trial completion until data read-out. CEO William Stilley expressed confidence in investor support and business outlook. AD04 aims to target specific genetic profiles in AUD treatment, with prior trials showing significant results without safety concerns.
Adial Pharmaceuticals (NASDAQ: ADIL; ADILW) announced that its CEO, William Stilley, has published an op-ed on Nasdaq.com, discussing the importance of addressing Alcohol Use Disorder (AUD). The op-ed highlights that over 30 million people in the U.S. are affected by AUD, leading to more than 95,000 deaths annually, and a cost of $250 billion to the nation. Stilley underscores the positive impact of their investigational drug AD04, currently in a pivotal Phase 3 trial for AUD. The trial's results from a Phase 2b study showed promising reductions in drinking frequency and no significant safety issues.
Adial Pharmaceuticals (NASDAQ: ADIL; ADILW) announced promising advancements in its adenosine analog development platform via its acquisition of Purnovate. The compounds developed show potency against targeted adenosine receptors while maintaining high solubility, achieving over 50 times more solubility than similar compounds. Initial studies indicate good oral bioavailability and pharmacological activity, particularly in reducing pain in rodents and demonstrating synergy with morphine and acetaminophen. These findings position Adial to potentially replace opioids and address addiction issues.
Adial Pharmaceuticals (NASDAQ: ADIL; ADILW) has entered into Securities Purchase Agreements for a private placement of 1,666,667 shares at $3.00 each, totaling $5 million. Leading the placement is Bespoke Growth Partners, Inc., contributing $2.5 million. The investment will be funded in two tranches: $500,000 immediately and the remaining $4.5 million following share registration. Adial focuses on addiction treatments, with its lead product AD04 currently in a pivotal Phase 3 trial for Alcohol Use Disorder (AUD), showing promising results in earlier trials.
Adial Pharmaceuticals announced key progress in its ONWARD Phase 3 clinical trial for AD04, aimed at treating Alcohol Use Disorder (AUD). The company achieved 100% screening and 90% enrollment targets, with 261 out of 290 expected subjects enrolled. Notably, 33% of screened patients tested positive for the genotype linked to AD04. The medication appears well-tolerated, with no serious adverse events reported. The retention rate stands at 84%, exceeding the projected 70%. Data from the trial is anticipated in Q1 2022.
Adial Pharmaceuticals has been added to the Russell Microcap® Index effective June 28, 2021. This inclusion follows the annual reconstitution of Russell indexes. The CEO stated that this reflects progress in increasing shareholder value, particularly with the clinical development of AD04 for alcohol use disorder through its ONWARD™ Phase 3 trial. Membership may enhance awareness and liquidity among institutional investors, aligning Adial with a vast $10.6 trillion in assets benchmarked against Russell indexes.
Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) announced the denial of its Fast Track Designation request from the FDA for its drug candidate AD04, aimed at treating Alcohol Use Disorder in pediatric and adult patients with Alcoholic Liver Disease. The FDA cited insufficient evidence of AD04's potential to address unmet medical needs given existing treatments. Despite FDA acknowledgment of the medical need, further data is required for reconsideration. The ongoing ONWARD Phase 3 trial continues to evaluate AD04's efficacy in genetically screened patients across multiple countries.
Adial Pharmaceuticals has announced plans to enter the genetic testing market following a Notice of Allowance from the U.S. Patent and Trademark Office. This patent covers the use of a genetic diagnostic panel in combination with its product AD04 for treating Alcohol Use Disorder (AUD) and potentially Opioid Use Disorder (OUD). The company estimates a multi-billion dollar market opportunity, anticipating that genetic evaluations can help identify patients likely to benefit from AD04. If approved, the patent will provide market exclusivity, enhancing Adial's commercial strategy.
Adial Pharmaceuticals (NASDAQ: ADIL; ADILW) acknowledges an article by Kate Julian in The Atlantic addressing the growing crisis of Alcohol Use Disorder (AUD) in the U.S., worsened by COVID-19 lockdowns. The company emphasizes that around 35 million Americans suffer from AUD annually, leading to significant health and economic burdens, costing roughly $250 billion yearly. Adial's investigational drug AD04 is currently being evaluated in the ONWARD™ Phase 3 trial aimed at treating AUD, showing promising results in previous trials.
Adial Pharmaceuticals (NASDAQ: ADIL; ADILW) has successfully completed a $2.1 million private placement of 700,001 shares at $3.00 each. This transaction involved key investors including Bespoke Growth Partners and Keystone Capital Partners. Following SEC approval, the company received $1,809,000, having initially secured $291,003. Adial is currently conducting the ONWARD Phase 3 clinical trial for its lead drug candidate, AD04, targeting alcohol use disorder, with continued optimism regarding its market potential and expansion into other indications.